Orphan Drug Pricing Heading To Negotiating Table in US?
Executive Summary
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.